Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom
Persistence Of Use Of Topical Prostaglandin Fixed Dose Combination In The United Kingdom Primary Care: An Observational Study In Thin
1 other identifier
observational
2,015
0 countries
N/A
Brief Summary
The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2010
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2010
CompletedFirst Submitted
Initial submission to the registry
August 26, 2010
CompletedFirst Posted
Study publicly available on registry
September 21, 2010
CompletedFebruary 2, 2021
June 1, 2011
6 months
August 26, 2010
February 1, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Frequency distribution of persistent and non-persistent patients across study cohorts
12 months
Frequency distribution of switchers, re-starters and discontinuing patients as well as patients commencing add-on therapy across the study cohorts
12 months
Time to discontinuation of each cohort
12 months
Secondary Outcomes (6)
Age and sex: Townsend Score of social deprivation, time since first THIN diagnosis of glaucoma or ocular hypertension
12 months
Procedures: Laser, Trabeculectomy, viscocanalostomy, deep sclerectomy
12 months
Ocular Pharmacological Treatments: Beta-blockers and Alpha-agonists
12 months
Prostaglandin mono-therapies
12 months
The cohort of patients which were evaluated in this study were investigated for the presence of history of disease for asthma, cardiovascular disease, diabetes, renal failure and systemic hypertension. The number of patients in each cohort were
12 months
- +1 more secondary outcomes
Study Arms (1)
fixed dose prostaglandin combination
Interventions
Eligibility Criteria
patients who had received a prescription for either Xalacom, Ganfort and DuoTrav, \> 18 years old, diagnosed with glaucoma or ocular hypertension, registered at the primary care practice for \> 12 months
You may qualify if:
- Patients who had received a prescription for either Xalacom, Ganfort and DuoTrav
- Greater than 18 years old
- Diagnosed with glaucoma or ocular hypertension
- Registered at the primary care practice for \> 12 months
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 26, 2010
First Posted
September 21, 2010
Study Start
February 1, 2010
Primary Completion
August 1, 2010
Study Completion
August 1, 2010
Last Updated
February 2, 2021
Record last verified: 2011-06